Intellia Therapeutics (NTLA) closed at $11.58 on Oct 19, 2026, up 1.4% on the day. The stock is down 4.6% over the past month, up 1.0% over three months, up 28.8% year to date and down 53.5% over the past year. It trades 37.3% below its 52-week high of $18.48 and 45.7% above its 52-week low of $7.95. The close sits below its 50-day moving average ($12.25) and below its 200-day moving average ($13.01).
NextPick tracks NTLA in its Cell / Gene Therapy basket alongside CRSP, BEAM, VCEL, PRME and EDIT. As of Oct 19, 2026, the basket's money-flow score is -18 (weak outflow), and the basket is down 4.8% over five sessions. Over the past month NTLA ranks 4th of 7 basket members by price change.
Over its last 8 reports the stock moved an average of 6.4% on the first trading day after earnings, beating the options-implied move in 3 of 8.
Over the last 8 reports, NTLA moved an average of 6.4% on the first trading day after earnings. The move beat the options-implied move in 3 of 8 reports.
No — the Oct 19, 2026 close of $11.58 is 11.0% below the 200-day average of $13.01.
NTLA closed 37.3% below its 52-week high of $18.48.
NextPick groups NTLA with CRSP, BEAM, VCEL, PRME and EDIT in its Cell / Gene Therapy basket.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
